Navigation Links
Two common diabetes drugs double the risk of fractures in women
Date:12/9/2008

Two common diabetes drugs rosiglitazone and pioglitazone are linked to higher fracture rates in women, according to a meta-analysis in CMAJ by a team of researchers from the University of East Anglia in the United Kingdom and Wake Forest University in the United States http://www.cmaj.ca/press/080486.pdf.

The drugs, called thiazolidinediones, help improve glycemic control and decrease insulin resistance in patients with diabetes.

The researchers looked at 10 randomized controlled trials of at least one year's duration involving 13 715 diabetes patients taking thiazolidinediones and those not taking the therapy. They found significantly reduced bone density in the lumbar spine and at the hip in women on the drugs.

It appears that long-term thiazolidinedione use doubles the risk of fractures among women with type 2 diabetes, without a significant increase in fracture risk in men. The researchers estimate that a fracture would occur in 1 out of 21 women at high risk of fracture who are taking thiazolidinedione for one year and among low risk women, there would be 1 fracture in every 55 if these drugs are taken for more than a year.

With more than 4 million users of thiazolidinediones in the United States alone in 2006, "the public health impact may be considerable," write Dr. Yoon Loke and coauthors. "If one assumes that half of those users were women and that the baseline risk of fractures is similar to that found in the ADOPT study, an estimated 30 000 excess fractures may have occurred if these women had been prescribed thiazolidinediones rather than metformin for more than a year."

The researchers call for further investigation into the underlying causes of this apparent sex-specific effect.

In a related commentary http://www.cmaj.ca/press/081713.pdf, Dr. Lorraine Lipscombe of the Institute for Clinical Evaluative Sciences and the University of Toronto writes that "clinical drug trials are often underpowered to detect unanticipated and rare adverse effects, and a standardized postmarketing surveillance process is needed." She cautions that the net benefit of these drugs is unclear, and there are other effective drugs that can control glycemia with fewer adverse events.


'/>"/>

Contact: Kim Barnhardt
kim.barnhardt@cma.ca
613-731-8610 x2224
Canadian Medical Association Journal
Source:Eurekalert

Related medicine news :

1. UK junior doctors gaining less experience of common procedures
2. New insights into common knee injuries
3. High and mighty: first common height gene identified by researchers behind obesity gene finding
4. Figure Skater Peggy Fleming, HealthSaver Says: Take Pains For Back Strains, 2nd Most Common Doctor Complaint
5. Exelixis Commences Public Offering of Common Stock
6. Common misdiagnosis: most women believe they have a yeast infection when they dont
7. Business Executives Discuss National Health Care Reform at Conference Sponsored by The Century Foundation, with Support from The Commonwealth Fund, and AARP
8. New Expert Report Dispels Common Myths About Aspartame
9. Common Foot Myths Trip Us Up
10. AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange
11. Allergy-Induced Asthma More Common in Affluent Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... ... (PVDF) based sleep diagnostics sensors, announced today it had completed the first phase ... a mix of domestic and rest of world (ROW) authorized dealers specializing in ...
(Date:5/23/2017)... Pa. (PRWEB) , ... May 23, 2017 , ... ... plans to open The Alexis Joy D’Achille Center for Women’s Behavioral Health at ... care available in western Pennsylvania for women suffering from pregnancy-related depression. Construction of ...
(Date:5/23/2017)... , ... May 23, 2017 , ... New England Journal ... Crisis Worthy of a Policy Response”, -The Rory Staunton Foundation Calls on Health & ... for the Prevention of Sepsis ( http://www.rorystauntonfoundation.org ) today reported on a new study ...
(Date:5/23/2017)... ... May 23, 2017 , ... London, May 23, 2017: Walter Schindler, the Founder ... as a Guest Speaker and Contributor to a weeklong series of classes, meetings, field ... , Walter Schindler and SAIL Capital have received an ...
(Date:5/23/2017)... ... May 23, 2017 , ... Drs. Allen ... peri-implantitis in Las Vegas, NV, and the importance of treating it ... consultation and leading care for peri-implantitis, with or without a referral. As experienced ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... 2017 Global Health Intelligence (GHI), the ... , published its 2017 ranking of the Best-Equipped ... extensive data analysis from GHI,s hospitals database for Latin ... the region. The GHI database covers 86% of the hospitals ... 130 data points for each institution in key areas such ...
(Date:5/9/2017)... 2017  Demonstrating its commitment to representing research- ... the Pharmaceutical Research and Manufacturers of America (PhRMA) ... will now have to meet new research and ... to join PhRMA. "By putting in ... a clear message that being a member of ...
(Date:5/6/2017)... --  Provista , a proven leader in the supply chain ... Jim Cunniff as the company,s new president and ... to Provista, including most recently serving as the president and ... . He assumed his new role with Provista on May ... Provista," says Jody Hatcher , president, Sourcing and Collaboration ...
Breaking Medicine Technology: